The Opioid Epidemic as Corporate Crime: What the Sacklers Knew
Internal Purdue Pharma documents, state attorney general lawsuits, and congressional testimony establish that the Sackler family—specifically the Raymond Sackler branch led by Richard, Jonathan, and David—received detailed, real-time sales and addiction data showing OxyContin was being abused and causing deaths as early as 1997, a full year after launch. Rather than halt aggressive marketing, they weaponized minimizing addiction risk as a sales strategy, personally directing a deceptive campaign that has now been adjudicated as fraudulent in multiple jurisdictions. This is not a case of corporate negligence but of documented, board-level knowledge and deliberate concealment—making it one of the clearest examples of elite corporate crime in modern American history.
Evidence for
- A 2019 Massachusetts Attorney General lawsuit, citing internal Purdue emails, revealed that Richard Sackler personally directed sales representatives to 'hammer' doctors with the message that OxyContin's addiction risk was 'less than one percent,' a figure Purdue's own data contradicted by at least 1999.
- Purdue's own internal 'Kick' database, disclosed in litigation and reported by the Los Angeles Times in 2016, tracked pharmacies and doctors suspected of enabling diversion and abuse—meaning executives had a real-time map of the epidemic they were simultaneously fueling and concealing from regulators.
- A 2007 federal guilty plea by Purdue Frederick Co. (Purdue's parent entity) for 'misbranding' OxyContin resulted in $634 million in fines, with three executives—Michael Friedman, Howard Udell, and Paul Goldenheim—pleading guilty personally, establishing that deceptive marketing was an institutional, executive-level practice, not rogue behavior.
- Leaked internal presentation slides from 1996, surfaced in the 2021 Purdue bankruptcy proceedings, show Richard Sackler at the OxyContin launch party framing the coming opioid wave as a 'blizzard of prescriptions' he intended to generate—demonstrating foreknowledge of scale, not an accident of overprescribing.
- Investigative journalist Patrick Radden Keefe's 2021 book 'Empire of Pain,' drawing on thousands of pages of sealed depositions, documents Sackler family members receiving quarterly reports flagging OxyContin abuse hotspots, indicating the board was systematically informed of addiction consequences throughout the 2000s.
- Whitney Webb and other investigative journalists have documented the Sacklers' use of philanthropic institutions—the Louvre, the Tate, the Met—as reputational laundering mechanisms while the internal record shows active suppression of addiction data, a pattern consistent with what Peter Dale Scott calls 'deep state' corporate capture of regulatory oversight.
Evidence against
- The Sacklers' legal team has consistently argued that OxyContin was FDA-approved with appropriate labeling, that prescribing decisions belonged to individual physicians, and that the family acted in good faith on the scientific consensus about pain management that existed in the late 1990s.
- Multiple bankruptcy settlement negotiations resulted in a 2021 deal (later partially overturned by the Supreme Court in Harrington v. Purdue Pharma, 2024) without any Sackler member pleading guilty to criminal charges, which skeptics of the 'corporate crime' framing cite as evidence the legal record is more ambiguous than activists claim.
- Some public health scholars argue that the opioid epidemic's roots predate OxyContin and include systemic failures by the DEA, FDA, state medical boards, and the broader pain-management movement—meaning singling out the Sacklers risks obscuring a distributed institutional failure.
- Purdue Pharma's defenders note that generic opioid manufacturers and distributors like McKesson, AmerisourceBergen, and Cardinal Health contributed equally or more to pill volume yet received far less public scrutiny, suggesting selective prosecution driven partly by the Sacklers' visibility as a named family.
Verified Sources
Open Veils conclusion
High confidenceThe evidentiary record—spanning internal emails, the 'Kick' abuse-tracking database, state AG lawsuits, and sealed depositions—establishes beyond reasonable institutional doubt that senior Sackler family members received addiction and diversion data in real time and chose marketing acceleration over public health disclosure. The absence of criminal prosecution for family members is not evidence of innocence but of the asymmetric application of criminal law to elite actors, a pattern Catherine Austin Fitts and Whitney Webb have documented across pharmaceutical and financial sectors. The 2024 Supreme Court ruling blocking the bankruptcy shield that would have granted Sacklers blanket civil immunity without criminal accountability represents a rare institutional acknowledgment that the settlement structure itself was constructed to evade justice. Future accountability likely depends on state-level criminal referrals and the continued unsealing of Purdue's internal document archive.
The core factual claim—that Sackler family board members possessed contemporaneous knowledge of OxyContin addiction and diversion data while directing deceptive marketing—is supported by primary documents in active litigation and has survived adversarial legal scrutiny in multiple jurisdictions.
Ask Open Veils a follow-up
More investigations